Ehlers-Danlos Syndrome — a clinically and genetically heterogeneous group of heritable connective tissue disorders comprising 13 subtypes under the 2017 International Classification, unified by defects in collagen synthesis, processing, or structural integrity, and affecting an estimated 1 in 500 to 1 in 5,000 individuals depending on subtype, with the hypermobile subtype (hEDS) representing the most common form at perhaps 1 in 500 to 1 in 5,000 (no causative gene identified as of the 2017 nosology revision), the classical subtype (cEDS) caused by COL5A1 or COL5A2 pathogenic variants affecting type V collagen with a frequency of approximately 1 in 20,000 to 1 in 40,000, the vascular subtype (vEDS) caused by COL3A1 pathogenic variants affecting type III procollagen — the most severe EDS subtype, defined by a high risk of arterial dissection and rupture, bowel perforation, and uterine rupture, with a median survival historically estimated at 48 years and arterial complications beginning in the second and third decades — the kyphoscoliotic subtype caused by PLOD1 or FKBP14 pathogenic variants, and the classical-like subtype (clEDS) caused by TNXB variants affecting tenascin-X, characterized across all subtypes by joint hypermobility, skin hyperextensibility or fragility, and atrophic scarring in varying combinations, and in hEDS specifically associated with a constellation of comorbidities including chronic widespread musculoskeletal pain, postural orthostatic tachycardia syndrome (POTS) from autonomic dysfunction, dysautonomia, and mast cell activation syndrome (MCAS) — produces its diverse phenotype through the downstream effects of abnormal extracellular matrix composition on connective tissue biomechanics throughout the body, with the severity and organ involvement determined by the specific collagen type affected (fibrillar collagen defects in cEDS/vEDS producing structural fragility, tenascin-X deficiency in clEDS producing proprioception and skin texture changes, lysyl hydroxylase deficiency in kyphoscoliotic EDS producing pyridinoline crosslink deficiency and progressive muscular hypotonia alongside severe kyphoscoliosis), and with hEDS representing a distinct pathophysiological entity in which the hypermobility, pain amplification, and autonomic dysfunction represent interconnected mechanisms whose genetic basis remains under active investigation, with current research examining α2-collagen chains, TNXB variants of uncertain significance, and connective tissue gene network polymorphisms. The multidisciplinary management of EDS engages clinical genetics for molecular diagnosis in genetically defined subtypes and clinical diagnosis under the 2017 hEDS criteria, vascular surgery and interventional radiology for arterial surveillance and emergency arterial management in vEDS, cardiology for aortic root monitoring and autonomic assessment, rheumatology for joint and pain management, physiotherapy for joint stabilization and pacing programs, pain management specialists for chronic pain in hEDS, immunology/allergy for MCAS management, gastroenterology for gastrointestinal dysmotility, electrophysiology and cardiology for POTS pharmacological management, neurology for dysautonomia assessment, orthopedics for joint subluxation and surgical stabilization, and psychology for chronic pain adjustment and health anxiety management.
Ehlers-Danlos Syndrome technology platforms — whether supporting the Ehlers-Danlos Society patient registry and MCAS/POTS comorbidity tracking applications used by the growing hEDS community; cardiovascular surveillance scheduling systems coordinating the annual CT angiography and MRI surveillance that is the standard of care for vascular EDS and the only means of detecting asymptomatic arterial aneurysm and dissection before catastrophic rupture; physiotherapy and multi-disciplinary chronic pain management coordination systems managing the exercise pacing programs, joint protection protocols, and specialist team coordination that underpin hEDS pain management; multi-disciplinary connective tissue clinic and cardiology coordination portals integrating genetics, vascular surgery, cardiology, rheumatology, physiotherapy, and allied health appointments across what are often geographically dispersed specialist teams; or emergency alert scheduling platforms managing vascular EDS emergency department protocol notification and surgical team pre-registration — must maintain the availability and performance standards demanded by the arterial emergency risk of vEDS, the complex chronic pain and comorbidity burden of hEDS, and the lifelong multidisciplinary coordination that all EDS subtypes require. This guide explains why EDS tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the vascular emergency, chronic pain comorbidity, and multi-disciplinary coordination complexity of modern Ehlers-Danlos Syndrome care.
Why Ehlers-Danlos Syndrome Tech Platforms Require Specialized Monitoring Attention
EDS management is defined by the coexistence of an urgent arterial emergency risk (in vEDS) and a complex chronic condition management profile (in hEDS and other subtypes) that together span the full spectrum of clinical urgency — from the annual arterial surveillance appointment that prevents arterial rupture in vEDS to the daily pain pacing program that determines functional capacity in hEDS, from the emergency department pre-notification protocol that reduces vascular EDS mortality to the MCAS trigger-avoidance records that prevent anaphylactoid reactions in a population with complex medication sensitivities. Technology failures across these domains translate directly into missed arterial surveillance windows, disrupted pain management programs, and absent emergency protocols in a patient population with high rates of medical complexity and frequently inadequate access to subtype-specific expertise.
Vascular EDS arterial surveillance platforms are life-critical. Vascular EDS — caused by COL3A1 pathogenic variants — carries a high risk of spontaneous arterial dissection and rupture, with the medium-sized arteries including the celiac, superior mesenteric, renal, and iliac arteries and the aorta at risk from the second decade of life onward. Annual CTA or MRI surveillance of the arterial tree is the standard of care for early detection of aneurysmal dilation before spontaneous rupture. Platforms managing arterial imaging scheduling, prior imaging comparison records, and vascular surgery referral coordination must be available at every surveillance appointment where the radiologist and vascular surgeon are comparing this year's CTA with prior studies to identify interval dilation. Monitor vascular surveillance platforms at 1-minute intervals during clinical hours, with immediate escalation.
POTS and dysautonomia management platforms govern hEDS quality of life. POTS — affecting an estimated 25–50% of hEDS patients — requires platforms managing tilt table testing records, heart rate response to orthostatic challenge, pharmacological management records (ivabradine, fludrocortisone, beta-blockers, midodrine), non-pharmacological intervention records (compression garment prescriptions, salt and fluid loading protocols, exercise conditioning programs), and cardiology follow-up coordination. POTS management is highly individualized and medication adjustments depend on prior trial records and current symptom burden. Monitor POTS management platforms at 1-minute intervals during clinical sessions.
MCAS comorbidity tracking platforms protect against anaphylactoid events. Mast cell activation syndrome in hEDS patients creates a complex polysensitivity profile where medication, food, and environmental triggers must be documented, tracked, and communicated across the entire care team. MCAS trigger documentation, antihistamine ladder prescriptions, emergency epinephrine prescriptions, and anaphylactoid event records must be accessible when the immunologist is adjusting the mast cell stabilizer regimen or when the emergency department is treating an acute MCAS event. Monitor MCAS management platforms at 1-minute intervals during clinical and emergency hours.
Emergency department protocol systems protect vEDS patients. Vascular EDS patients carry documented emergency protocol cards and benefit from pre-registration of their diagnosis and management needs at regional emergency departments. Platforms managing emergency protocol documentation, vascular surgery on-call notification pre-authorization, and emergent CTA or MRI ordering pathways — which override standard ED triage to prioritize imaging and vascular surgical assessment in any vEDS patient presenting with acute chest, abdominal, or back pain — must be available at the moment of emergency presentation. Monitor emergency protocol platforms at 1-minute intervals, 24/7.
Physiotherapy coordination platforms maintain functional capacity in chronic EDS. The joint stabilization programs, graded exercise pacing protocols, and multi-disciplinary pain management coordination that are the primary treatment for hEDS-related chronic pain and functional limitation depend on platforms maintaining physiotherapy session records, home exercise program documentation, activity diary records, and specialist team communication notes. Physiotherapy platform failures delay the program adjustments that prevent deconditioning cycles and joint injury. Monitor physiotherapy coordination platforms during business and extended clinical hours.
What to Monitor on an Ehlers-Danlos Syndrome Tech Platform
Ehlers-Danlos Society Patient Registry and Disease Documentation
Monitor patient registry enrollment records documenting EDS subtype, causative gene variant (in genetically defined subtypes), and clinical feature inventory across the 13 subtype categories; MCAS comorbidity tracking records including mast cell activation trigger logs, reaction severity grading records, and cumulative allergen and medication sensitivity profiles; POTS comorbidity records including orthostatic heart rate response documentation, pharmacological management records, and non-pharmacological protocol records; dysautonomia and autonomic function study records; pain visual analogue scale and patient-reported outcome measure records; quality of life assessment records (SF-36, EQ-5D adapted for EDS); functional capacity assessment records; and patient registry update and data export records at 1-minute intervals during clinical and business hours. Alert immediately — registry platform failures during a clinical genetics consultation for a newly diagnosed vascular EDS patient being registered in the Ehlers-Danlos Society registry delay the epidemiological documentation and the systematic comorbidity baseline assessment that will guide vascular surveillance scheduling and enable the registry data contributions that drive the EDS research informing surveillance guidelines.
Cardiovascular Surveillance Scheduling and Vascular EDS Arterial Imaging
Monitor annual CTA and MRI vascular surveillance scheduling records for vEDS patients including prior imaging comparison request workflows (ensuring the current study is formally compared with the most recent prior study for interval change), arterial aneurysm and dissection tracking records with vessel segment dimensions across serial imaging studies, vascular surgery referral coordination for any surveillance study showing interval dilation or new finding, aortic root surveillance records for subtypes with aortic involvement, echocardiography scheduling records for mitral valve prolapse surveillance (present in a subset of EDS patients), and imaging result communication workflows at 1-minute intervals during clinical hours. Alert immediately — cardiovascular surveillance platform failures during the annual vascular surveillance review for a vEDS patient comparing the current celiac artery CTA with the prior year's study to detect aneurysmal dilation lose the comparison imaging and measurement records whose absence may result in the radiologist and vascular surgeon being unable to quantify interval change — the key determinant of whether conservative surveillance or surgical/endovascular intervention is indicated in a patient for whom an undetected enlarging aneurysm carries a risk of fatal spontaneous rupture.
Multi-Disciplinary Connective Tissue Clinic Coordination
Monitor multi-disciplinary clinic appointment scheduling records coordinating genetics, vascular surgery, cardiology, rheumatology, physiotherapy, pain management, immunology/allergy, gastroenterology, neurology, orthopedics, and psychology across a single care episode or coordinated annual review; specialist team communication and letter records; shared care plan documentation; surgical consultation records; medication reconciliation records across the multiple specialists managing complex hEDS pharmacological regimens; and transition to adult care documentation for pediatric EDS patients at 1-minute intervals during clinical hours. Alert immediately — multi-disciplinary clinic coordination platform failures during the annual connective tissue clinic review for a hEDS patient being assessed by genetics, rheumatology, physiotherapy, and cardiology in a single day lose the integrated shared care record that allows each specialist to document their component of the management plan in a shared platform rather than disparate systems — creating the documentation fragmentation that delays the shared care plan update and increases the risk of conflicting management recommendations from specialists who cannot see each other's concurrent documentation.
Physiotherapy and Pain Management Coordination
Monitor physiotherapy session records including joint stabilization exercise prescriptions, graded activity pacing program records, home exercise program compliance tracking, functional capacity assessment records, activity diary submissions, pain visual analogue scale trends across therapy episodes, and physiotherapy outcome measure records; multi-disciplinary pain management records including pain specialist consultation notes, pain psychology session records, cognitive behavioral therapy documentation, pharmacological pain management records (duloxetine, pregabalin, amitriptyline, NSAIDs with gastrointestinal and vascular risk documentation for vEDS), topical analgesia records, and interventional pain procedure records; occupational therapy adaptive equipment and joint protection records; and inpatient pain management admission records during business and extended clinical hours. Alert on sustained failures — physiotherapy platform failures delay the program adjustment that prevents the deconditioning cycle — where reduced physical activity from pain leads to further joint instability, which increases pain and further reduces activity — that is the most common pathway for functional decline in hEDS, and whose interruption requires an individualized pacing program recalibration that physiotherapy platform records make possible.
POTS and Autonomic Function Management
Monitor tilt table testing records documenting heart rate and blood pressure response to orthostatic challenge with POTS diagnostic criteria documentation (heart rate increase ≥30 bpm within 10 minutes of upright tilt without orthostatic hypotension), pharmacological management records including ivabradine, fludrocortisone, beta-blocker, midodrine, and pyridostigmine prescribing records with dose adjustment history, compression garment prescription records, fluid and salt protocol records, exercise conditioning program records, Holter monitoring and event recorder records for arrhythmia assessment, and cardiology and electrophysiology follow-up records at 1-minute intervals during clinical hours. Alert immediately — POTS management platform failures during a cardiology appointment for a hEDS patient with treatment-refractory POTS being evaluated for dose escalation of ivabradine or addition of fludrocortisone lose the prior treatment trial records and current medication dose history that are essential for safe pharmacological escalation in a patient who may have tried multiple agents at varying doses with varying degrees of efficacy and intolerance.
MCAS Management and Trigger Documentation
Monitor mast cell activation syndrome trigger log records documenting food, medication, environmental, and physical triggers with severity grading; antihistamine ladder prescription records (H1 and H2 antihistamine combinations, mast cell stabilizers including cromolyn sodium and ketotifen); emergency epinephrine auto-injector prescription and training records; anaphylactoid event records with trigger identification and management documentation; immunology/allergy specialist consultation records; medication hypersensitivity records (critical for avoiding iatrogenic MCAS reactions during medical procedures); and MCAS dietary restriction records at 1-minute intervals during clinical and emergency hours. Alert immediately — MCAS management platform failures during an immunology appointment for a hEDS patient with MCAS and multiple medication hypersensitivities being evaluated for a mast cell stabilizer addition lose the trigger log and medication hypersensitivity records whose absence may lead to inadvertent exposure to a documented trigger during a procedure or the prescription of an agent to which the patient has a documented MCAS reaction.
Emergency Department Protocol and Vascular EDS Emergency Management
Monitor vascular EDS emergency department pre-registration records at regional emergency departments including documented COL3A1 variant confirmation, emergency management protocol summary (imaging-first approach with CTA or MRI before physical examination palpation of any suspected vascular or visceral site, avoidance of invasive procedures without surgical backup, direct vascular surgical team notification), vascular surgery on-call notification pre-authorization records, emergent imaging ordering pathway records, and vascular EDS emergency card documentation at 1-minute intervals, 24/7. Alert immediately — emergency protocol platform failures at the moment a vEDS patient presents to an emergency department with acute abdominal pain create the risk that standard ED triage proceeds with physical examination, laboratory workup, and delayed imaging in a patient for whom the highest priority is immediate CTA to detect and characterize arterial or visceral emergencies before any manipulation that could precipitate or worsen an arterial tear.
Authentication and Patient Identity
Monitor authentication at 1-minute intervals, 24/7. EDS programs coordinate across genetics, vascular surgery, cardiology, rheumatology, physiotherapy, pain management, immunology/allergy, gastroenterology, neurology, orthopedics, and psychology — authentication failures simultaneously block every specialist managing a patient whose subtype-specific risks range from immediately life-threatening arterial emergency in vEDS to complex chronic pain and autonomic dysfunction in hEDS, and where the multi-disciplinary platform is the connective tissue of the coordinated care team.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, registry systems, vascular surveillance scheduling platforms, multi-disciplinary clinic coordination systems, POTS and MCAS management platforms, physiotherapy coordination systems, and emergency protocol management platforms. Certificate errors disrupt the arterial surveillance scheduling, emergency protocol access, and chronic condition management workflows of EDS care across all subtypes.
HIPAA and Genetic Privacy Considerations
Ehlers-Danlos Syndrome technology platforms handle sensitive PHI including molecular genetic diagnostic records identifying COL3A1 pathogenic variants in vEDS patients (conferring predictive information about arterial rupture risk that has life insurance, health insurance, and employment implications), POTS and dysautonomia functional assessment records, MCAS trigger and medication hypersensitivity records, chronic pain documentation with psychological assessment components, and emergency management protocol records at regional emergency departments. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing vEDS molecular diagnostic records — where COL3A1 variant confirmation is the basis for the annual arterial surveillance program, the emergency department protocol, cascade family testing recommendations, and family planning decisions — genetic privacy protections are paramount, as unauthorized disclosure of vEDS genetic status could result in life insurance discrimination or employment consequences for an individual already managing a life-limiting condition. For platforms managing MCAS documentation with extensive medication hypersensitivity records — where this information is shared across multiple specialists and emergency settings to prevent inadvertent MCAS triggers — access controls must balance broad clinical accessibility with privacy protections appropriate for records documenting an individual's most severe physiological vulnerabilities. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for EDS programs managing genetic, vascular, autonomic, immunological, and chronic pain PHI across a complex multidisciplinary care continuum.
Alerting Strategy for Ehlers-Danlos Syndrome Tech Platforms
Continuous 24/7 immediate alerting: Emergency department protocol and vascular EDS emergency management systems. A vEDS patient presenting to the ED with acute pain requires immediate protocol access — delays of minutes increase mortality risk.
Immediate alerting during clinical hours: Vascular surveillance scheduling platforms, cardiovascular imaging and comparison records, POTS and autonomic management platforms, MCAS trigger and medication hypersensitivity platforms, and multi-disciplinary clinic coordination portals.
Immediate alerting during clinical and emergency hours: Authentication systems, MCAS emergency management records, and any platform managing anaphylactoid event documentation or emergency epinephrine protocols.
Sustained-failure alert (10–15 minutes): Physiotherapy coordination, pain management documentation, occupational therapy records, genetic counseling documentation, and patient registry platforms during business hours.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms EDS platform availability from the geographies where specialized connective tissue clinics, vascular surgery centers, and dysautonomia programs serve this population — important for a condition spectrum where expert centers are geographically concentrated and remote patients depend on telemedicine and digital coordination platforms.
Status Page for Ehlers-Danlos Syndrome Care Team Communication
A real-time status page gives vascular surgeons reviewing annual surveillance CTA findings, cardiologists managing POTS pharmacotherapy, immunologists adjusting MCAS management, physiotherapists coordinating pain pacing programs, and emergency departments managing vEDS emergencies immediate platform visibility without requiring inbound IT support contact. During a vascular surveillance platform outage at the moment a vEDS patient's annual CTA is being read, a status page enables the radiology team to activate the paper-based comparison workflow — pulling the prior printed CTA report from the patient's physical chart — while IT restores the imaging comparison system.
Include the status page URL in vascular EDS emergency management protocols at all pre-registered emergency departments, vascular surveillance downtime procedures, multi-disciplinary clinic coordination plans, and physiotherapy program continuity documentation.
Vigilmon Setup for Ehlers-Danlos Syndrome Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Emergency department protocol — vEDS (24/7) | 1 min | Slack + PagerDuty (24/7) | | Vascular EDS arterial surveillance scheduling | 1 min | Slack + PagerDuty (clinical hours) | | CTA/MRI imaging comparison and vascular records | 1 min | Slack + PagerDuty (clinical hours) | | POTS and autonomic function management | 1 min | Slack + PagerDuty (clinical hours) | | MCAS trigger and medication hypersensitivity records | 1 min | Slack + PagerDuty (clinical + emergency hours) | | Multi-disciplinary connective tissue clinic coordination | 1 min | Slack + PagerDuty (clinical hours) | | Ehlers-Danlos Society patient registry | 2 min | Slack (business hours) | | Physiotherapy and pain management coordination | 2 min | Slack (business hours) | | Cardiology POTS follow-up records | 2 min | Slack (business hours) | | Immunology/allergy MCAS follow-up records | 2 min | Slack (business hours) | | Orthopedics joint management records | 2 min | Slack (business hours) | | Patient and family communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure vascular EDS emergency department protocol systems with 24/7 immediate alerting
- Add arterial surveillance scheduling and imaging comparison platforms with immediate clinical-hours alerting
- Configure POTS and autonomic management platforms with immediate clinical-hours alerting
- Add MCAS trigger, medication hypersensitivity, and emergency epinephrine records with clinical and emergency hours alerting
- Configure multi-disciplinary clinic coordination portal with immediate clinical-hours alerting
- Add patient registry, physiotherapy, pain management, and specialist follow-up records with sustained-failure alerting
- Configure occupational therapy and orthopedics records with sustained-failure alerting
- Enable SSL certificate monitoring across all genetics, vascular, autonomic, MCAS, physiotherapy, and clinic coordination domains
- Add the status page URL to vEDS emergency protocols, arterial surveillance downtime procedures, and multi-disciplinary clinic coordination plans
Conclusion
Ehlers-Danlos Syndrome technology platforms are embedded in clinical decisions where vascular surveillance platform availability during the annual CTA review for a COL3A1-confirmed vascular EDS patient — where the vascular surgeon comparing this year's celiac artery diameter of 12 mm with last year's recorded diameter of 10 mm, identifying the 2 mm interval enlargement that crosses the threshold for vascular surgical consultation, must access the prior imaging comparison data in the surveillance platform to make the management recommendation that prevents spontaneous arterial rupture in a 34-year-old whose maternal aunt died from a splenic artery rupture at age 31 — cannot be delayed by a platform outage at the moment the comparison measurement is being made; where POTS management platform availability during a cardiology appointment for a hEDS patient who has tried fludrocortisone with ankle edema, midodrine with supine hypertension, and beta-blockers with exercise intolerance and is being evaluated for ivabradine — where the cardiologist must access the complete prior medication trial records documenting the specific doses, side effects, and trial durations of each agent attempted to confirm that ivabradine addition is the appropriate next step rather than retreating to an agent that has already failed at adequate dosing — determines whether the medication adjustment is guided by complete pharmacological history or partial recall; where MCAS trigger documentation platform availability when a hEDS patient with 47 documented MCAS triggers, including reactions to polyethylene glycol-containing medications, contrast dye, and iodine-containing topicals, presents to a pre-operative assessment clinic before elective shoulder stabilization surgery — where the anesthesiology team must access the complete MCAS trigger and medication hypersensitivity records to plan an anesthetic that avoids all documented triggers and ensures rescue epinephrine and antihistamine protocols are in place — determines whether the perioperative plan is built from complete allergy documentation or a patient's recall of a complex medication sensitivity profile that no individual can reliably recite in a pre-operative setting; where emergency department protocol platform availability at the moment a vEDS patient presents to a regional emergency department with acute-onset back pain at 2 AM — where the emergency physician checking the system for any existing vEDS emergency protocol for this patient must immediately access the COL3A1 confirmation, the imaging-first management protocol, and the on-call vascular surgery notification pathway documented in the emergency protocol platform to activate the appropriate management pathway rather than proceeding with standard ED abdominal examination and pain management that could delay the emergent CTA that will confirm or exclude aortic dissection — is the difference between an imaging-first management pathway that identifies and treats the arterial emergency and a delayed imaging pathway that allows an arterial dissection to propagate during the waiting period: a vascular surveillance platform that fails when the vascular surgeon is making the aneurysm growth measurement that triggers surgical referral, a POTS management platform unavailable when the cardiologist is selecting the next pharmacological agent based on prior trial records, an MCAS documentation system inaccessible when the anesthesiologist is planning the perioperative allergy management for elective surgery, an emergency protocol system offline when the emergency physician is managing the acute back pain presentation of a patient with COL3A1-confirmed vEDS — these are not IT incidents. They are disruptions in the management of a syndrome spectrum where one subtype carries an arterial rupture risk that makes surveillance scheduling and emergency protocol access immediately life-critical, another subtype creates a chronic pain, autonomic dysfunction, and immunological complexity that demands continuously available multi-disciplinary coordination platforms, and where the heterogeneity of the syndrome means that affected individuals may carry risks spanning both the urgent and chronic ends of the management spectrum.
Uptime monitoring gives Ehlers-Danlos Syndrome tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to vascular surgery programs, connective tissue clinics, autonomic dysfunction services, MCAS specialist programs, physiotherapy departments, emergency departments, and compliance auditors that platform operational reliability matches the arterial emergency, chronic comorbidity, and lifelong multi-disciplinary coordination complexity of modern Ehlers-Danlos Syndrome care.
Start monitoring your Ehlers-Danlos Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #EhlersDanlosSyndrome #EDS #hEDS #vEDS #COL3A1 #COL5A1 #connectiveTissueDisorder #POTS #dysautonomia #MCAS #mastCellActivation #vascularEDS #arterialSurveillance #chronicPain #jointHypermobility #rareDisease #HIPAA #healthtech #digitalhealth #uptime #sre